RLYB Rallybio Corp: Enterprise Value to EBITDA Ratio
Biotechnology holding Rallybio Corporation (RLYB) is currently utilizing its existing reserves to fund costly scientific research. The quotes provided below with the 0.00 metric complement the management picture, where experienced executives are focusing on discovering breakthrough therapies for rare pathologies. Meanwhile, Rallybio Corporation (RLYB) attracts distinguished biologists with an academic atmosphere, granting them extensive creative freedom and lucrative stock option programs.
Comprehensive metric breakdowns and analytics for rallybio.com (RLYB)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
RLYB - Company Net Income|Future Profit Rallybio Corporation|RLYB - Market Cap to Earnings|Forward P/E Multiple Rallybio|RLYB - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Rallybio Corporation|RLYB - Operating income before deduction of amortization|Earnings per share for the last twelve months Rallybio|RLYB - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months rallybio.com|RLYB - Earnings per share increase in current year|Earnings growth forecast for next year Rallybio Corporation
- company sales and revenue statistics:
Summary company analysis:Rallybio Corp. RLYB
For Rallybio Corporation (RLYB), which is developing innovative immunology for rare diseases with support from Johnson & Johnson, the EV/EBITDA valuation trend serves as a filter for market noise, linking the total enterprise value to its operating profitability before taxes and interest. By analyzing this chart, an investor determines the real value of assets relative to generated cash flow, making it possible to identify whether the asset is overbought or undervalued during its clinical growth phase.
Competitors of Rallybio Corporation
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|Business Value to Operating Income Before Depreciation MNKD|Amphastar - EV/EBITDA Multiple|PCRX - EV/EBITDA Multiple|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TBPH (theravance.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aquestive Therapeutics, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SCPH|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to EBITDA|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entera Bio (ENTX)|Enterprise Value to EBITDA Ratio HYFT|ABVC: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPIX|Enterprise Value to EBITDA Ratio Quantum BioPharma Ltd. QNTM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization FibroGen Corp FGEN|Telomir Pharmaceuticals Corp (TELO) - Company Value to EBITDA|RANI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation SNYR (Synergy CHC Corp)|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PULM (Pulmatrix Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Company Value to EBITDA Aptorum APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|EV/EBITDA Multiple cbdMD Inc. YCBD|PRFX: Enterprise Value to EBITDA Ratio|Altamira Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|LIPO: EV/EBITDA Multiple|OPTN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Company Value to EBITDA Procaps Group PROC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|Qilian International Corp - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|Business Value to Operating Income Before Depreciation TFFP
